Winton Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.08M | Sell |
49,994
-6,769
| -12% | -$147K | 0.06% | 404 |
|
|
2025
Q1 | $1.38M | Sell |
56,763
-2,510
| -4% | -$60.9K | 0.08% | 229 |
|
|
2024
Q4 | $1.24M | Buy |
59,273
+4
| +0% | +$83 | 0.08% | 215 |
|
|
2024
Q3 | $1.18M | Sell |
59,269
-5,126
| -8% | -$102K | 0.08% | 206 |
|
|
2024
Q2 | $997K | Buy |
64,395
+110
| +0.2% | +$1.7K | 0.07% | 241 |
|
|
2024
Q1 | $1.02M | Buy |
+64,285
| New | +$1.02M | 0.07% | 241 |
|
|
2023
Q2 | – | Sell |
-20,158
| Closed | -$334K | – | 836 |
|
|
2023
Q1 | $334K | Buy |
20,158
+5,597
| +38% | +$92.8K | 0.02% | 795 |
|
|
2022
Q4 | $271K | Sell |
14,561
-8,943
| -38% | -$166K | 0.02% | 807 |
|
|
2022
Q3 | $302K | Buy |
+23,504
| New | +$302K | 0.02% | 793 |
|
|
2021
Q4 | – | Sell |
-142,529
| Closed | -$755K | – | 1086 |
|
|
2021
Q3 | $755K | Buy |
142,529
+5,313
| +4% | +$28.1K | 0.04% | 649 |
|
|
2021
Q2 | $789K | Buy |
137,216
+14,797
| +12% | +$85.1K | 0.04% | 658 |
|
|
2021
Q1 | $564K | Buy |
122,419
+36,545
| +43% | +$168K | 0.03% | 817 |
|
|
2020
Q4 | $287K | Buy |
85,874
+26,640
| +45% | +$89K | 0.02% | 1065 |
|
|
2020
Q3 | $176K | Buy |
+59,234
| New | +$176K | 0.01% | 1361 |
|
|
2019
Q2 | – | Sell |
-12,454
| Closed | -$64K | – | 1152 |
|
|
2019
Q1 | $64K | Buy |
+12,454
| New | +$64K | ﹤0.01% | 1046 |
|